Malaria: a new treatment to slow down resistance

February 18, 2015, Institut de Recherche pour le Développement (IRD)
Credit: IRD / J. Montmarché : Medical consultation in Benin

The appearance of malaria parasites resistant to medicines is one of the main obstacles in combating the disease. In order to slow down this phenomenon, it is essential to avoid exposing the pathogen to the same molecules. For this reason, researchers at the IRD and their partners in OCEAC in Cameroon are testing new treatments. They have recently demonstrated the efficacy of a "bi-therapy", which combines artesunate (a derivative of artemisinin, recommended by the WHO) with Malarone (or Malanil). The latter has been administered up to now as a preventative treatment for travellers or as a treatment in the industrialised nations, because it is so expensive. The fact that its patent entered the public domain in 2013 has made it possible to envisage its use among populations living in regions where the disease is endemic.

Globally, the number of cases of malaria has been decreasing for several years now. Nonetheless, a spectre haunts the minds of the researchers: the resistance to drugs shown by the malaria parasites. These parasites, in particular Plasmodium falciparum, are in fact capable of developing resistance to all the treatments that currently exist. To slow down as much as possible the emergence and expansion of this resistance, it is necessary to use a variety of drugs and to rationalise their use. For the less the pathogens are exposed to the same molecules, the less they will develop.

Proven efficacy

To do this, for more than 20 years researchers from the IRD and the Organisation for the Coordination of the Fight against Endemic Diseases in Central Africa (OCEAC) have been evaluating the efficacy of in Cameroon. At the present time, the treatment recommended by the WHO is based on the administration of a , called "bi-therapy", using artemisinin. The research team has recently demonstrated the efficacy of the combination of artesunate, a derivative of artemisinin, with Malarone (or Malanil). This drug has been used up until now principally as a for travellers on temporary visits to a country where the disease is endemic, as well as being used therapeutically to treat malaria imported into the industrialised nations, because until now it has been prohibitively expensive.

A winning combination

When administered on its own, Malarone showed some therapeutic failures (10.3%) among the 340 young Cameroonian patients in the study, children of less than five years of age; for the most part these failures were due to re-infection during treatment. However, in combination with artesunate, this drug has proved even more effective than traditional bi-therapy and the number of cases of relapse within 28 days is less marked.

Strains of P. falciparum resistant to Malarone do exist. But systematically combining this drug with a derivative of artemisinin guarantees the patient a certain efficacy of treatment. In fact it is not very probable at the present time that a strain resistant to both of these drugs at once will be encountered.

The patent for Malarone entered the in 2013.  Generic drugs began to be manufactured, bringing down the price of the drug. Its use in therapeutic combination with a derivative of artemisinin can therefore now be envisaged for the populations living in the countries where the disease is endemic.

Explore further: Malaria combination drug therapy for children

More information: "Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children." Journal of Infectious Diseases, 2014: 1962–1971. DOI: 10.1093/infdis/jiu341

Related Stories

Malaria combination drug therapy for children

December 30, 2014
A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with uncomplicated malaria in settings where multiple parasite species cause malaria according to Tim Davis from University ...

Researchers identify genetic marker of resistance to key malaria drug

December 18, 2013
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease. The research ...

Team discovers reasons for malaria's drug resistance

December 11, 2014
Scientists from Nanyang Technological University (NTU) have discovered exactly how the malaria parasite is developing resistance towards the most important front-line drugs used to treat the disease.

Whole plant therapy shows promise to beat malaria parasites' drug resistance

January 5, 2015
For decades, physicians and public health officials worldwide have been thwarted by the malaria parasite's ability to evolve resistance to the succession of drugs developed to treat it. But now University of Massachusetts ...

New artemisinin-based treatment against malaria promising

November 8, 2011
For some time now, artemisinin, derived from a Chinese herb, has been the most powerful treatment available against malaria. To avoid the malaria parasite becoming resistant, the World Health Organisation (WHO) strongly recommends ...

Recommended for you

Tick bite protection: New CDC study adds to the promise of permethrin-treated clothing

May 24, 2018
The case for permethrin-treated clothing to prevent tick bites keeps getting stronger.

Early lactate measurements appear to improve results for septic patients

May 24, 2018
On October 1, 2015, the United States Centers for Medicare and Medicaid Services (CMS) issued a bundle of recommendations defining optimal treatment of patients suffering from sepsis, a life-threatening response to infection ...

Dengue: Investigating antibodies to identify at-risk individuals

May 23, 2018
Using an original mathematical and statistical analysis method, a team of scientists from the Institut Pasteur partnered with researchers from the United States and Thailand to analyze a Thai cohort that has long been a focus ...

Fatty liver disease research set to benefit from stem cell advance

May 23, 2018
Scientists have developed a lab-based system for studying the most common type of liver disease, paving the way for research into new therapies.

More frequent checks control MRSA in newborns, but can hospitals afford them?

May 22, 2018
The more often a hospital can check its newborns for deadly MRSA germs, the more likely it will be that they are contained, according to a new study.

Could we predict the next Ebola outbreak by tracking the migratory patterns of bats?

May 22, 2018
Javier Buceta, associate professor of bioengineering, Paolo Bocchini, associate professor of civil and environmental engineering, and postdoctoral student Graziano Fiorillo of Lehigh University have created a modeling framework ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.